Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Type 1 Diabetes, Closed Loop, Insulin, Q...
Phase Not Applicable
Enrollment 20
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today. The treatment for type 1 diabetes is insulin therapy. In recent years, new systems have emerged, so-called "semi-closed loop" systems, also called automated insulin therapy, which have proven their superiority in terms of quality of life and glycemic balance in adults and children over 6 years old. Since January 24, 2024, the HAS now recognizes the indication of the semi-closed loop for the YPSOPUMP model in children aged 2 to 6 years. This is the first reimbursement in France of a closed loop system for the 2-6 year old age group. There are currently few studies comparing the quality of life of children in semi-closed loop versus other treatments (open loop or injections). Regarding quality of life, the studies found mainly concern the contribution for parents and the improvement of adolescents' sleep as in the study by Erin C Cobry et al from 2020 (6). Our study therefore aims to demonstrate an improvement in quality of life but also in diabetes balance in type 1 diabetic patients on a closed loop insulin pump versus open loop or injections in the pediatric population aged 2-6 years.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • An improvement in the score on the general quality of life questionnaire in pediatrics PedsQL 4.0 which will be evaluated before the implementation of the semi-closed loop, at 1 month and 6 months after the implementation of the semi-closed loop. (the assessment of quality of life via the PedsQL 4.0 questionnaire will be evaluated before the implementation of the semi-closed loop, at 1 month and 6 months after the implementation of the semi-closed loop.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-17
Completion: 2026-12
Eligibility
Age: 2 Years – 6 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondation Lenval
Principal Investigators:
  • Céline Gouillard-Darnaud, MD (PRINCIPAL_INVESTIGATOR) - Fondation Lenval
Contact Information
Study Contact:
Aline JOULIE, PHD
+33492030520
joulie.a@chu-nice.fr
Valentine FOURNY-SARGHAT, MD
+33602273069
valentine.fourny@free.fr
Interventions
N/A
Study Locations (1 sites)
Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval, Nice, France 06000 France
Eligibility Criteria
Inclusion Criteria: * -Patients aged 2 to 6 years inclusive * Presenting type 1 diabetes on insulin therapy * Social security affiliates * Patient initiating semi-closed loop treatment * Family (at least one parent or representative of parental authority) agreeing to follow the training necessary for continuous measurement of glucose in real time. * collection of non-opposition from one of the two parents or the representative of parental authority agreement Exclusion Criteria: * Opposition to participation in research involving humans or opposition to the use of data or samples and associated data (withdrawal of non-opposition).
Conditions Nonalcoholic Fatty Liver Disease, Type 2...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The global rise in the prevalence of obesity paved the way for the increased prevalence of yet another obesity-related complication significant enough to be considered within the roster of major public health threats: non-alcoholic fatty liver disease (NAFLD). In this follow-up study, the investigators will attempt to decipher the natural history of hepatic steatosis among patients with type 2 diabetes mellitus (T2DM) using state-of-the-art methods in a well-characterized Saudi cohort. The investigators aim also to validate existing biomarkers of disease severity and explore the pathogenesis of progressive disease using metabolic profiling technologies. A total of 1000 adult Saudi patients (males and females) with T2DM will be recruited. Those with co-morbidities, including hepatic decompensation, will be excluded. Participants will be followed three times for a total of 10 years/patient (Year 2, Year 5, and Year 10), and measures such as dietary evaluations, anthropometrics, and urine, stool, and blood examinations will be performed. Patients who develop NAFLD will be noted, and patterns/changes in the metabolic profile will be examined. For this specific grant (the first 2 years of the whole project), the investigators will be able to recruit the study cohort, do the baseline anthropometric, imaging, and biochemical measurements, and report the prevalence of NAFLD among patients with T2DM. This information will be the basis of subsequent follow-up and allow for validating potential diagnostic and prognostic biomarkers. This project will be of high importance at the national level since it will create awareness in the local medical community of the current severity status of NAFLD in the kingdom and will be used as a tool to promote public health awareness in the community.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of hepatic steatosis in T2DM (15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-03-23
Completion: 2030-12-31
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King Saud University
Collaborators: King Fahad Medical City
Principal Investigators:
  • Assim Alfadda, MD (PRINCIPAL_INVESTIGATOR) - King Saud University
Contact Information
Study Contact:
Assim A Alfadda, MD
0557021171
aalfadda@ksu.edu.sa
Rukhsana Gul, MD
0501387295
Rgul@ksu.edu.sa
Interventions
N/A
Study Locations (1 sites)
King Fahad Medical City, Riyadh, Select A State Or Province 11525 Saudi Arabia
Eligibility Criteria
Inclusion Criteria: * Subject has provided informed consent prior to screening * Men and women aged 18 to 60 years * T2DM Exclusion Criteria: * Evidence of hepatic decompensation (ascites, clinical jaundice-bilirubin ≥ 40 µmol/L, encephalopathy) * Preexisting hepatocellular carcinoma * Other preexisting hepatic or extrahepatic malignancy * Previous overt ischemic heart disease (myocardial infarction or acute coronary syndrome) or cerebrovascular disease (stroke or transient ischemic attack) * Previous coronary artery bypass grafting, angioplasty, or stenting * Any other issues that, in the opinion of the investigators, may preclude satisfactory completion of the study protocol
Conditions Diabetic Foot, Foot Ulcer, Ulcer Foot, D...
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, prospective, controlled clinical trial evaluating the efficacy of a single layer placental-based allograft and standard of care in the management of nonhealing diabetic foot ulcers.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: XWRAP — Application of XWRAP + standard of care for up to 12 weeks.

Primary Outcomes

  • Wound Closure (1-12 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-08-26
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Applied Biologics, LLC
Collaborators: SerenaGroup, Inc.
Contact Information
Study Contact:
Bennett Sarver
1-833-865-6300
info@serenagroups.com
Thomas Serena, MD
1-833-865-6300
info@serenagroups.com
Yaliliy Perez
954-940-0208
yalilyp@royalresearchcorp.com
Royal Research
Interventions
  • Other: XWRAP — Application of XWRAP + standard of care for up to 12 weeks.
Study Locations (1 sites)
Royal Research, Hollywood, Florida 33024 United States
Eligibility Criteria
Inclusion Criteria: * The potential subject must be at least 18 years of age or older. * The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus. * If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the CAMPX study. * The potential subject must consent to using the prescribed offloading method for the duration of the study. * The potential subject must agree to attend the weekly study visits required by the protocol. * The potential subject must be willing and able to participate in the informed consent process. * The potential subject must have participated in the CAMPX trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint. Exclusion Criteria: * The potential subject is known to have a life expectancy of \< 6 months. * The potential subject's target ulcer is not secondary to diabetes. * The target ulcer is infected or there is cellulitis in the surrounding skin. * The target ulcer exposes tendon or bone. * There is evidence of osteomyelitis complicating the target ulcer. * There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. * The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). * The potential subject has applied topical steroids to the ulcer surface within one month of initial screening. * The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer. * The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. * The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer. * The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months. * The potential subject has end stage renal disease requiring dialysis. * The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments. * The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment. * The potential subject did not participate in the CAMPX trial. * The potential subject participated in the CAMPX trial and was not randomized to the SOC only arm. * The potential subject participated in the CAMPX trial and achieved complete closure.
Conditions Asthma
Phase PHASE3
Enrollment 138
Locations 67 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: FF/UMEC/VI — FF/UMEC/VI will be administered.
  • Device: ELLIPTA — FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
  • Drug: FF/VI — FF/VI will be administered.

Primary Outcomes

  • Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24 (Baseline (Week 0) and Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-04-24
Completion: 2027-01-28
Eligibility
Age: 12 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Drug: FF/UMEC/VI — FF/UMEC/VI will be administered.
  • Device: ELLIPTA — FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
  • Drug: FF/VI — FF/VI will be administered.
Study Locations (67 sites)
GSK Investigational Site, Birmingham, Alabama 35244 United States
GSK Investigational Site, Mobile, Alabama 36608 United States
GSK Investigational Site, Paradise Valley, Arizona 85253 United States
GSK Investigational Site, Bakersfield, California 93301-4205 United States
GSK Investigational Site, Huntington Beach, California 92647 United States
GSK Investigational Site, Mission Viejo, California 92691 United States
GSK Investigational Site, Rolling Hills Estates, California 90274 United States
GSK Investigational Site, Colorado Springs, Colorado 80909 United States
GSK Investigational Site, Aventura, Florida 33180 United States
GSK Investigational Site, Miami, Florida 33165 United States
Eligibility Criteria
Inclusion Criteria: * Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent. * Participants who have a diagnosis of asthma as defined by the National Institutes of Health \[NIH, 2020\] at least 1 year prior to Visit 0. * Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of \>250 to \<=500 microgram (mcg)/day fluticasone propionate, or equivalent). * In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent). * Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy. * A best pre-bronchodilator FEV1 \>40% to \<=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative. Exclusion Criteria: * Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1. * Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration) * History of Life-threatening Asthma * Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.). * Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco\]) within 12 months prior to Visit 1.
Conditions COPD, Emphysema, Asthma COPD Overlap, Em...
Phase Not Applicable
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Other: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap

Primary Outcomes

  • Site and Mechanism(s) of Expiratory Airflow Limitation (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-01-01
Completion: 2027-12-01
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gelb, Arthur F., M.D.
Principal Investigators:
  • Arthur F Gelb, MD (PRINCIPAL_INVESTIGATOR) - Clin Prof Geffen School of Medicine at UCLA Medical Center
  • Arthur F Gelb, MD (STUDY_DIRECTOR) - Clin Prof Geffen School of Medicine at UCLA Medical Center
Contact Information
Study Contact:
Arthur F Gelb, MD
562-633-2204
afgelb@msn.com
Christine Fraser
562-633-2204
familyfrase@msn.com
Arthur F Gelb, MD
562-633-2204
afgelb@msn.com
Arthur F Gelb MD
Interventions
  • Other: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Study Locations (2 sites)
Arthur F Gelb MD, Lakewood, California 90712 United States
Arthur F Gelb MD, Lakewood, California 90712 United States
Eligibility Criteria
Inclusion Criteria: * asthma- copd overlap * emphysema in smokers with smoking history \> 15 pack years * COPD/ bronchitis and bronchiectasis in smokers with smoking history * \>15 pack years Exclusion Criteria:other pulmonary or systemic diagnosis * non smokers * any other pulmonary diagnosis * pulmonary fibrosis

Structure and Function MRI of Asthma

NCT02351141
Recruiting
Conditions Asthma
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will apply 129Xenon and/or 3He image acquisition and analysis methods in 200 asthma patient volunteers in order to characterize and probe the relationship between lung structure and function using imaging.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Hyperpolarized Noble Gas MRI — Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.

Primary Outcomes

  • Ventilation Defect Percent as measured by Xenon-129 and/or Helium-3 MRI (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2015-01
Completion: 2030-12
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Grace Parraga
Principal Investigators:
  • Grace E Parraga, PhD (PRINCIPAL_INVESTIGATOR) - Robarts Research Institute, The University of Western Ontario
Contact Information
Study Contact:
Grace E Parraga, PhD
519-931-5265
gparraga@robarts.ca
Angela P Wilson, RRT
519-931-5777
awilson@robarts.ca
Grace E Parraga, PhD
519-931-5265
gparraga@robarts.ca
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
Interventions
  • Other: Hyperpolarized Noble Gas MRI — Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study Locations (1 sites)
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London, Ontario N6A 5B7 Canada
Eligibility Criteria
Inclusion Criteria: * Subjects male and female aged 18-60 with a clinical diagnosis of asthma * Smoking history ≤ 1 pack/year * Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent * Subject is judged to be in otherwise stable health on the basis of medical history * Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater.) * FEV1 \>60% predicted Exclusion Criteria: * Patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material * Patient is unable to perform spirometry or plethysmography maneuvers * Subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants.) (At the discretion of the MRI Technologist/3T Manager) * In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia. * Patient is pregnant
Conditions Asthma; Eosinophilic, Severe Asthma
Phase PHASE4
Enrollment 220
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Benralizumab Prefilled Syringe — Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

Primary Outcomes

  • Predictive value of early blood gene expression signature of Benralizumab (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-10-11
Completion: 2026-11
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nantes University Hospital
Collaborators: AstraZeneca, Ministère de la Santé - France
Contact Information
Study Contact:
François-Xavier BLANC, MD-PHD
+33240165545
xavier.blanc@chu-nantes.fr
Youssef TRIGUI, MD-PHD
Centre hospitalier Intercommunal Aix-en-Provence
Hakima OUKSEL, MD
CHU Angers
Interventions
  • Drug: Benralizumab Prefilled Syringe — Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Study Locations (20 sites)
Centre hospitalier Intercommunal Aix-en-Provence, Aix-en-Provence, France
CHU Angers, Angers, France
CHU Bordeaux, Bordeaux, France
CHRU Brest, Brest, France
CHU Dijon, Dijon, France
CHU Grenoble, Grenoble, France
Hôpital Bicêtre - AP-HP, Le Kremlin-Bicêtre, France
CH Mans, Le Mans, France
CHU Lille, Lille, France
Hospices Civils de Lyon, Lyon, France
Eligibility Criteria
Inclusion Criteria: * Patients between 18 and 75 years old. * Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.: * asthma requiring high doses of ICS (\>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and/or systemic corticosteroids to be controlled over one year, * and/or uncontrolled asthma despite the later medications, * and/or a controlled asthma worsening after decreasing medications, * Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter * ACQ-7 score ≥ 1,5 at M0. * ≥ 3 exacerbations in the 12 months prior to screening visit M-1. * Eosinophil blood count ≥ 0,3 G/L at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G/L and \< 0,3 G/L, an eosinophilic phenotype defined by at least 1 of the following criteria will be required: * Fractional Exhaled Nitric Oxide (FeNO) \> 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit. * Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit. * Patients who provide written informed consent prior to participation in the study Exclusion Criteria: * Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/COPD overlap syndrome). * Non-adherent patients to inhaled treatment (ICS + LABA). * Active smokers or former smokers exceeding 20 packs year. * Exacerbation at inclusion visit M0. * Active malignancy or malignancy in remission over less than 5 years. * Active parasitic infection or parasitic infection in the past 24 weeks. * Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20) * Patients requiring other immunosuppressive and immunomodulator drugs * Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma * Patients requiring other biotherapy than Benralizumab that affects the immune system * SARS-COV2 infection * Pregnancy, lactation, or patients with childbearing potential refusing efficient contraceptive method. * Patients under psychiatric condition altering their comprehension and their ability to give informed consent. * Patients already enrolled in a clinical interventional research. * Patients not affiliated to a health insurance plan * Patients under guardianship, curators or safeguard of justice
Conditions Asthma
Phase PHASE4
Enrollment 242
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT), required to investigate this. This study will use these imaging methods to visually assess and measure individual patients' airways and determine whether abnormal airway structures impact how well they respond to inhaled and orally delivered medications. We anticipate finding that abnormal airway structures make inhaled medications less effective, but that they do not affect the response to oral medications.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Inhaled corticosteroid (ICS) — In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.
  • Drug: Oral Corticosteroid (OCS) — In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.

Primary Outcomes

  • Biological response to additional ICS (12 weeks)
  • Biological response to add-on OCS (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-06-02
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 242 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McMaster University
Contact Information
Study Contact:
Sarah Svenningsen, PhD
(905) 522-1155 Ext. 32195
svennins@mcmaster.ca
Yonni Friedlander, PhD
(905) 522-1155 Ext. 32195
yfriedla@stjoes.ca
Sarah Svenningsen, PhD
905-522-1155
svennins@mcmaster.ca
St. Joseph's Healthcare Hamilton
Interventions
  • Drug: Inhaled corticosteroid (ICS) — In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.
  • Drug: Oral Corticosteroid (OCS) — In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.
Study Locations (2 sites)
St. Joseph's Healthcare Hamilton, Hamilton, Ontario L8N4A6 Canada
Western University, London, Ontario N6A 3K7 Canada
Eligibility Criteria
Inclusion Criteria: * Able and willing to provide written informed consent. * Able and willing to comply with the study protocol. * Males and females ≥ 18 years of age. * Asthma diagnosed by a respiratory physician. * Airway hyperresponsiveness (defined as methacholine PC20 ≤8mg/mL) and/or bronchodilator reversibility (defined as post-bronchodilator FEV1 improvement ≥200mL and 12%) in the last 6 months * ACQ ≥1.5 during the screening period. * Sputum eosinophils ≥3% and/or FeNO ≥35ppb during the screening period. Exclusion Criteria: * Current smoker, defined as someone having smoked ≥1 cigarette/day (or vape/pipe/cigar/marijuana) for ≥30 days within 12 months prior to screening. * Pregnant or breastfeeding * Non-English speaking * Oral corticosteroids in past 1-month * Biologic therapy in past 6-months * Unable to perform proper MDI technique during the screening period * Other pulmonary diseases (e.g., chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to screening. * Unable to undergo MRI. Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist). Suffers from any physical, psychological, or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
Conditions Airway Inflammation, Chronic Obstructive...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled. Participants will: 1. Answer questions about their health and symptoms. 2. Give blood samples 3. Have lung function tests and other standard check-ups. 4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Peripheral Blood Immune Cell Subset Profiling by Mass Cytometry (CyTOF) (baseline)
  • Serum Cytokine Levels by ELISA (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-01
Completion: 2026-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Ningbo University
Contact Information
Study Contact:
chao Cao, Doctor
+86-0574-87085233
caocdoctor@163.com
chao Cao, Doctor
+86-0574-87089878
caodoctor@163.com
The First Affiliated Hospital of Ningbo University
Interventions
N/A
Study Locations (1 sites)
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang China
Eligibility Criteria
Inclusion Criteria 1. Age ≥18 years (≥40 years for COPD patients). 2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria. 3. PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 \<80% predicted) 4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms. 5. Healthy controls: normal lung function, FeNO \<20 ppb, total IgE \<100 IU/mL, no chronic disease, smoking \<10 pack-years, no immunosuppressant use within 3 months. Exclusion Criteria 1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer. 2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy. 3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy) 4. Pregnant or lactating women. 5. Patients with poor compliance as judged by the investigators. 6. Subjects currently participating in other clinical studies.

Asthma Symptom Perception Study

NCT06612294
Recruiting
Conditions Asthma
Phase NA
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Asthma affects 8% of the United States population ages \>60 years and causes considerable harm: older adults are 4 times more likely to die from asthma and have twice the risk of hospitalization. The burden of asthma is notably greater among minoritized older adults. Research suggests that perception of expiratory airflow limitation may be a major determinant of asthma outcomes in older adults, and that older adults are substantially less aware of airway obstruction than younger adults. These observations suggest that perception of airflow limitation is a potential target for improving outcomes of older patients with asthma. The research team completed a pilot randomized controlled trial (RCT) of an intervention that trains older adults with asthma to better perceive expiratory airway obstruction through feedback via peak expiratory flow (PEF) prediction and couples this feedback with motivational interviewing (MI) to promote change in asthma self-management behaviors. Compared to an attention control, the intervention improved PEF, perception of airflow limitation and asthma control. In this project, the research team will conduct a fully powered RCT to test the intervention's efficacy among 300 adults ages ≥60 years with uncontrolled asthma who are on controller medications (daily maintenance or as needed) recruited from underserved inner-city medical practices in New York City. Patients will be randomized to the intervention or a time and attention matched educational control. The intervention and control will be delivered in 3 sessions over 6 weeks. The study will test the impact of the intervention on perception of expiratory airflow limitation in older adults with asthma, examine the efficacy of the intervention for improvements in lung function (PEF), self-reported asthma control (Asthma Control Questionnaire \[ACQ\] scores), quality of life (Asthma Quality of Life Questionnaire \[AQLQ\] scores), and emergency department and hospital use, and test the intervention's impact on mean daily ICS dose used (daily maintenance and as needed). Data will be collected at baseline, 1-month, 6-months (primary analyses of effectiveness) and 12-months post-intervention. In secondary analyses, the research team will test the sustainability of treatment effects with vs. without the booster treatment session (active booster vs. attention control booster) delivered immediately after the 6-month assessment on outcomes at 12-months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: PEF Interventional Session — 3 sessions over 6 weeks for asthma management
  • Behavioral: Control Sessions — 3 sessions over 6 weeks for asthma management
  • Behavioral: Control Booster — A single booster session after the 6-months assessments are completed.
  • Behavioral: Active booster — A single booster session after the 6-months assessments are completed.

Primary Outcomes

  • Peak expiratory flow (PEF) Values (at baseline, 1-month, 6-months, and 12-months post-intervention)
  • Mean daily ICS dose used (at baseline, 1-month, 6-months, and 12-months post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-18
Completion: 2028-12-22
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: Albert Einstein College of Medicine, Yeshiva University, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Juan Wisnivesky, MD, DrPH (PRINCIPAL_INVESTIGATOR) - Division Chief, General Internal Medicine
Contact Information
Study Contact:
Juan Wisnivesky, MD, DrPH
212-824-7845
juan.wisnivesky@mountsinai.org
Dhanya Chanumolu, MPH
332-777-5754
dhanya.chanumolu@mountsinai.org
Dhanya Chanumolu, MPH
332-777-5754
dhanya.chanumolu@mountsinai.org
Ichan School of Medicine at Mount Sinai
Interventions
  • Behavioral: PEF Interventional Session — 3 sessions over 6 weeks for asthma management
  • Behavioral: Control Sessions — 3 sessions over 6 weeks for asthma management
  • Behavioral: Control Booster — A single booster session after the 6-months assessments are completed.
  • Behavioral: Active booster — A single booster session after the 6-months assessments are completed.
Study Locations (2 sites)
Ichan School of Medicine at Mount Sinai, New York, New York 10029 United States
Albert Einstein College of Medicine, The Bronx, New York 10461 United States
Eligibility Criteria
Inclusion Criteria: * Age \> 60 years * English or Spanish speaking * Self-report or physician diagnosis of asthma \>1 year ago * Uncontrolled asthma Exclusion Criteria: * Dementia * Chronic obstructive pulmonary disease (COPD), or other chronic respiratory illnesses, * Congestive Heart Failure (CHF, New York Heart Association \[NYHA\] stages 4-5) * Cigarette smoking \>15 packs-years
Conditions Asthma in Children, Genetic Disease, Inf...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • type 2 inflammation indicators (Outpatient visits for the first time)
  • pulmonary function indicators (Outpatient visits for the first time)
  • single nucleotide polymorphism (Outpatient visits for the first time)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-30
Completion: 2025-12-30
Eligibility
Age: 3 Years – 14 Years
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Institute of Respiratory Disease
Contact Information
Study Contact:
Lihong Sun, M.D.
13719240285
sunlihong9797@126.com
Lanying Cheng
15918742726
chenglanyingmed@163.com
Lihong Sun, master
+86-13719240285
sunlihong9797@126.com
Guangzhou institute of respiratory disease
Interventions
N/A
Study Locations (1 sites)
Guangzhou institute of respiratory disease, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: 1. All children with asthma diagnosis accord with the GINA in 2023 edition; 2. Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies; 3. In front of the hospital 2 weeks without antibiotics, systemic hormone medication history; 4. There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc. Exclusion Criteria: 1. Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission; 2. Children with primary immunodeficiency disease; 3. The children and their families failed to cooperate or refused the experimental observation.
Conditions Asthma (Diagnosis), Adult
Phase NA
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy of Indonesian Asthma Gymnastic for stable asthmatic patients in all asthma classification. The outcome measurements includes 6 minutes walk test, Asthma Control Test, peak flow rate value, and lung function. All participants have been in routine standard treatment of asthma (medication, education of healthy life style and smoking cessation).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Indonesian Asthma Gymnastic exercise — Aerobic structured exercise designed for asthmatic patient consists of 8 phase: warming up, stretching, core movement I, core movement II, aerobics I-III, and cooling down

Primary Outcomes

  • Change in 6 minutes walk distance (Baseline, 4 weeks)
  • Asthma Control Test score (Baseline, 4 weeks)
  • Change in Forced Expiratory Volume in 1 second, Forced Vital Capacity, and FEV1/FVC ratio (Baseline, 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-06
Completion: 2026-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RSUP Persahabatan
Contact Information
Study Contact:
Veronika R Kurniawati
+62 87857355235
veronikarennykurniawati@gmail.com
RSUP Persahabatan
+62 87857355235
veronikarennykurniawati@gmail.com
RSUP Persahabatan
Siti C Widjanantie
+62 81348639827
RSUP Persahabatan
Interventions
  • Other: Indonesian Asthma Gymnastic exercise — Aerobic structured exercise designed for asthmatic patient consists of 8 phase: warming up, stretching, core movement I, core movement II, aerobics I-III, and cooling down
Study Locations (1 sites)
RSUP Persahabatan, Jakarta, Indonesia
Eligibility Criteria
Inclusion Criteria: * Diagnosed with stable asthma * Age 18-65 years old * Competent and willing to be included in the trial Exclusion Criteria: * Asthma exacerbation * Had other lung disease * Had neuromuscular disease affecting respiratory system